Delcath stock.
A Look At Delcath Systems' Liabilities . According to the last reported balance sheet, Delcath Systems had liabilities of US$11.1m due within 12 months, and liabilities of US$6.40m due beyond 12 months. Offsetting this, it had US$14.5m in cash and US$127.0k in receivables that were due within 12 months.
NEW YORK, Nov. 6, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced ...Delcath Systems, Inc. (NASDAQ: DCTH) observed an upward trajectory in its stock value during the extended trading session on Tuesday. The after-hours market saw a 6.22% surge, elevating Delcath stock to $2.39. This positive movement partially offset the earlier 24.50% decline, settling the regular session at $2.25. The surge was instigated by ...prer14a 1 a42519.htm delcath systems, inc. united states. securities and exchange commission. schedule 14a (rule 14a-101) information required in proxy statement. schedule 14a information. proxy statement pursuant to section 14(a) of the securities exchange act of 1934 (amendment no. __) r.Real stock prices are not the same as the last traded stock price. Real stock prices are adjustments to closing stock prices. The adjustments are used in a variety of ways, including dividends, the range of prices and the closing price of t...
NEW YORK, Jan. 19, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that the Company has reached a Special Protocol Assessment (SPA) agreement with the U.S. …Nov 22, 2023 · Delcath Systems stock has received a consensus rating of buy. The average rating score is and is based on 9 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Delcath ... DCTH | October 10, 2023. NEW YORK, Oct. 10, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that it will be participating in the Lytham Partners Fall 2023 Investor Conference taking place virtually on Tuesday, …
The 5 analysts offering 12-month price forecasts for Delcath Systems Inc have a median target of 18.00, with a high estimate of 22.00 and a low estimate of ...
The following institutional investors have sold Delcath Systems stock in the last 24 months: Kent Lake Capital LLC ($94.47K), and Cibc World Market Inc. ($5K). How much institutional selling is happening at Delcath Systems? Institutional investors have sold a total of 99,468 shares in the last 24 months. This volume of shares sold represents ...52 Week High. $7.99. 52 Week Low. $2.25. Data as of November 24, 2023 1:00 PM EST. Data Provided by Refinitiv. Minimum 15 minutes delayed. undefined. See a complete list …Legal Name Delcath Systems, Inc. Stock Symbol FRA:DV3P. Company Type For Profit. Contact Email [email protected]. Phone Number 2124892102. Delcath Systems is an interventional oncology company that focuses on the treatment of metastatic liver cancer. Its proprietary product Melphalan Hydrochloride for Injection for use with the Delcath …Delcath Systems, Inc. (NASDAQ:DCTH) released its quarterly earnings results on Monday, November, 13th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.10. The business earned $0.43 million during the quarter, compared to the consensus estimate of $0.68 million.Get the latest Delcath Systems, Inc. (DCTH) stock quote, history, news and other vital information to help you with your stock trading and investing. See the current price, performance outlook, earnings date, dividend yield, fair value and more.
About Us. Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary products are HEPZATO KIT™ (melphalan) for Injection/Hepatic Delivery System (HDS) and CHEMOSAT ® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP).
Delcath Systems Inc DCTH shares are moving higher on above-average volume Tuesday after the company announced FDA approval of HEPZATO KIT.. What To Know: The FDA approved Delcath's HEPZATO KIT for the treatment of adult patients with unresectable hepatic-dominant metastatic uveal melanoma (mUM), a rare, aggressive …
0001564590-16-017679.txt : 20160504 0001564590-16-017679.hdr.sgml : 20160504 20160504164539 ACCESSION NUMBER: 0001564590-16-017679 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENTSo DelCath stock is much less risk to play with than Celsion. On top of that, DelCath is less promoted than that from Celsion at this time. DelCath is potential undervalue if its Chemosat is ...Delcath Systems Inc (NASDAQ:DCTH) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more than ...According to the issued ratings of 4 analysts in the last year, the consensus rating for Delcath Systems stock is Buy based on the current 4 buy ratings for DCTH. The average twelve-month price prediction for Delcath Systems is $18.00 with a high price target of $21.00 and a low price target of $13.00. Learn more on DCTH's analyst rating history.Insider Buying: Delcath Systems, Inc. (NASDAQ:DCTH) COO Purchases $49,897.20 in Stock Ticker Report • about 1 month ago Delcath Systems, Inc. (NASDAQ:DCTH Get Free Report) COO John Purpura acquired 14,505 shares of the stock in a transaction dated Friday, October 13th. NEW YORK, Nov. 15, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material …
DCTH | 1 hour ago. NEW YORK, Nov. 15, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee ...Mar 30, 2023 · Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announces that ... Please contact Delcath’s transfer agent, American Stock Transfer and Trust Company, LLC 6201 15th Ave. Brooklyn, NY 11219 1-800-937-5449 www.amstock.com.A reverse stock split went into effect today for Delcath Systems (OTC: DCTH) — developer of the Chemostat hepatic delivery system for treating cancer. The 1-for-700 reverse stock split is meant to reduce the number of common stock shares and shares reserved for issuance to 1.2 million, from a previous 1.4 billion. The authorized number of ...Summary. Delcath Systems received FDA approval for its HEPZATO Kit device as a treatment for liver-dominant eye cancer, resulting in the stock price surging over $7.00. Concerns arise over the ...
When we look at Delcath Systems Inc’s average trading volume, we note the 10-day average is 0.54 million shares, with the 3-month average coming to 413.15K. Analysts gave the Delcath Systems Inc (DCTH) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.00.
prec14a 1 a42519.htm delcath systems, inc. united states. securities and exchange commission. schedule 14a (rule 14a-101) information required in proxy statement. schedule 14a information. proxy statement pursuant to section 14(a) of the securities exchange act of 1934 (amendment no. __) r.Delcath has undergone numerous cap raises over its three decades of history but almost as numerous reverse stock splits have kept the share count to about 11 million. The market cap is $83 M ...DELCATH SYSTEMS, INC. (Name of Registrant as Specified In Its Charter) ROBERT B. LADD ...Delcath Systems, Inc. Common Stock (DCTH) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Get the latest Delcath Systems, Inc. (DCTH) stock quote, history, news and other vital information to help you with your stock trading and investing. See the current price, performance outlook, earnings date, dividend yield, fair value and more.0001564590-15-006231.txt : 20150805 0001564590-15-006231.hdr.sgml : 20150805 20150805161855 ACCESSION NUMBER: 0001564590-15-006231 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT
Nov 30, 2023 · Stock analysis for Delcath Systems Inc (DCTH:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
0001193125-15-285097.txt : 20150810 0001193125-15-285097.hdr.sgml : 20150810 0001193125-15-285097.hdr.sgml : 20150810
Delcath is dedicated to revolutionizing the treatment of patients with cancer in their liver. Delcath Systems, Inc. is a commercial-stage interventional oncology company aiming to be the leader in targeted, safe and effective minimally-invasive treatments for patients with cancers in the liver. Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that today the US Food and Drug ...The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Delcath Systems Inc 50-day moving average is $3.38.Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Fintel reports that on August 15, 2023, HC Wainwright & Co. maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Analyst Price Forecast Suggests 436.15% Upside. As of August 2, 2023, the average one-year price target for Delcath Systems is 16.73. The forecasts range from a low of 10.10 to a high of $23.10.Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.10-Q 1 dcth-10q_20160630.htm 10-QDELCATH SYSTEMS, INC. (Name of Registrant as Specified In Its Charter) ROBERT B. LADD ...No changes to the price of Delcath Systems stock on the last trading day (Friday, 7th Feb 2020). During the last trading day the stock fluctuated 0% from a day low at $10.25 to a day high of $10.25.The price has fallen in 5 of the last 10 days and is down by -39.71% for this period.On average, Wall Street analysts predict that Delcath Systems's share price could reach $18.00 by Sep 7, 2024. The average Delcath Systems stock price ...The FDA approved Delcath Systems Inc's DCTH HEPZATO KIT (melphalan/Hepatic Delivery System).. The approval is as a liver-directed treatment for adult patients with metastatic uveal melanoma with ...US24661P8077. Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded in August 1988 and is headquartered in New York, NY.
Delcath Systems Stock Ownership FAQ. Who owns Delcath Systems? Delcath Systems ( NASDAQ: DCTH) is owned by 32.13% institutional shareholders, 8.64% Delcath Systems insiders, and 59.23% retail investors. Rosalind Advisors Inc is the largest individual Delcath Systems shareholder, owning 1.04M shares representing 4.71% of the company.NEW YORK, March 29, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic ...Delcath's stock price increased 34 percent on that news. There are no records showing that any Delcath officers or directors received options or bought stock in the weeks before the Fast Track ...At one point, Delcath's stock was delisted from NASDAQ and share price was trading at 2 cents on OTC exchange before numerous reverse splits. Investors have written off Delcath and thought it was ...Instagram:https://instagram. schd dividend datemutf amcpxntflexpensive quarters to look for Jun 1, 2023 · Delcath has undergone numerous cap raises over its three decades of history but almost as numerous reverse stock splits have kept the share count to about 11 million. The market cap is $83 M ... Nov 22, 2023 · When we look at Delcath Systems Inc’s average trading volume, we note the 10-day average is 0.54 million shares, with the 3-month average coming to 413.15K. Analysts gave the Delcath Systems Inc (DCTH) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.00. tan etf holdingsmsci nyse Nov 17, 2023 · finance.yahoo.com - September 5 at 5:40 PM. Delcath Systems, Inc. Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KIT™. finance.yahoo.com - September 1 at 3:21 PM. Delcath Systems (DCTH) Price Target Increased by 10.98% to 18.56. nitro wood review Nov 22, 2023 · 15.2%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: DCTH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week. Volatility Over Time: DCTH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks. The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.